'Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel' - A hypothesis that remains unproven: Editorial on Serebruany: 'Viewpoint: Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ticagrelor and elinogrel'

Thrombosis and Haemostasis

Volumn 108, Issue 6, 2012, Pages 1028-1030

  Schror, Karsten ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; CANGRELOR; CLOPIDOGREL; CYCLOOXYGENASE 2; ELINOGREL; EPTIFIBATIDE; ETORICOXIB; LUMIRACOXIB; PLACEBO; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; ROFECOXIB; TICAGRELOR; TIROFIBAN;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BRADYCARDIA; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DYSPNEA; HUMAN; KIDNEY DISEASE; LOADING DRUG DOSE; NEUTROPHIL; PRIORITY JOURNAL; THROMBOCYTE; TRANSFUSION RELATED ACUTE LUNG INJURY;

ACUTE LUNG INJURY; ADENOSINE; BLOOD TRANSFUSION; HUMANS; PLATELET AGGREGATION INHIBITORS; QUINAZOLINONES; SULFONAMIDES;

EID: 84871064862     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH12-07-0513     Document Type: Article

References (21)

1. Storey RF. Pharmacology and clinical trials of re-versibly-binding P2Y12 inhibitors. Thromb Hae-most 2011; 105 (Suppl 1): S75-81.
2. Storey RF, Becker RC, Harrington RA, et al. Characterization of dyspnoea in PLATO study patients treated with tiagrelor or clopidogel and its association with clinical outcomes. Eur Heart J 2011; 32: 2945-2953.
3. Schneider DJ. Mechanisms potentially contributing to the reduction in mortality associated with ti-cagrelor therapy. J Am Coll Cardiol 2011; 57: 685-687S.
4. Sillen H., Cook M., Davis P. Determination of unbound ticagrelor and it active metabolite (AR-C124910XX) in human plasma by equilibrium dialysis. J Chromat B AnalyTechnol Biomed Life Sci 2011; 879: 2315-2323.
5. Welsh RC, Rao SV, Zeymer U, et al. A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopido-grel in patient undergoing nonurgent percutaneous coronary intervention. The INNOVATE-PCI trial. Circ Cardiovasc Interv 2012; Epub ahead of print.
6. Serebruany VL. Reversible nature of platelet binding causing transfusion-related acute lung injury (TRALI) syndrome may explain dyspnea after ti-cagrelor and elinogrel. Thromb Haemost 2012; 108: 1024-1027.
7. Mason KD, Carpinelli MR., Fletcher JI, et al. Programmed anuclear cell death delimits platelet life span. Cell 2007; 128: 1173-1186
8. Toy P, Lowell C. TRALI - Definition, mechanisms, incidence and clinical relevance. Best Pract Res Clin Anaesthesiol 2007; 21: 183-193.
9. Toy, P., Gajic, O., Bacchett, IP., et al. Tr a n s fu s io n - re la te d acute lung injury: incidence and risk factors. Blood 2012; 119: 1757-1767.
10. Peter K, Schwarz M, Yläne J, et al. Induction of fibri-nogen binding and platelet aggregation as a potential intrinsic property of various glycoprotein IIb/ IIIa (alphaIIbeta3) inhibitors. Blood 1998; 92: 3240-3249.
11. Serebruany VL. Adenosine release: a potential explanation for the benefits of ticagrelor in the PLATelet inhibition and clinical Outcomes trial? Am Heart J 2011; 161: 1-4.
12. Van Giezen JJJ, Sidaway J, Glaves P, et al. Ticagrelor inhibits adenosine uptake in vitro and enhances adenosine-mediated hyperemia responses in a canine model. J Cardiovasc Pharmacol Ther 2012; 17: 164-172.
13. Gan, L-M, Wittfl A, Emanuelsson H, et al. Adeno-sine may mediate tiagrelor-induced dyspnea. J Am Coll Cardiol 2012; 59: E344.
14. Capone ML, Tacconelli S, Sciulli MG, et al. Clinical pharmacology of selective COX-2 inhibitors. Int J Immunopathol Pharmacol 2003; 16 (Suppl): 49-58.
15. Wiviott SD, Braunwald E, McCabe CH, et al. Prasu-gre l versus clop idog re l in patients w ith acute coronary syndromes. N Engl J Med 2007; 357: 2001-2015.
16. Serebruany VL. Viewpoint: paradoxical excess mortality in the PLATO trial should be independently verified. Thromb Haemost 2011; 105: 752-759.
17. Wallentin L, Becker RC, James SK, et al. The PLATO trial reveals further opportunities to improve outcomes in patients with acute coronary syndrome. Thromb Haemost 2011; 105: 760-762.
18. Ohman EM, Roe MT. Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Thromb Haemost 2011; 105: 763-765.
19. Mahaffey KW, Wojdyla DM, Becker CK, et al. Ti-cagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcome (PLATO) trial. Circulation 2011; 124: 544-554.
20. Kohli P, Udell JA, Murphy S, et al. Discharge aspirin dose and clinical outcome in patients with ACS: an analysis from the TRiTON-TIMI-38 study. J Am Coll Cardiol 2012; 59: E342.
21. Mehta SR, Tanguay JF, Eikelboom JW, et al. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 2010; 376: 1233-1243.